American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy
Research article published in Blood advances (2018)
Abstract
BACKGROUND: Clinicians confront numerous practical issues in optimizing the use of anticoagulants to treat venous thromboembolism (VTE). OBJECTIVE: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians and other health care professionals in their decisions about the use of anticoagulants in the management of VTE. These guidelines assume the choice of anticoagulant has already been made. METHODS: ASH formed a multidisciplinary guideline panel balanced to minimize potential bias from conflicts of interest. The McMaster University GRADE Centre supported the guideline development process, including updating or performing systematic evidence reviews. The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess evidence and make recommendations, which were subject to public comment. RESULTS: The panel agreed on 25 recommendations and 2 good practice statements to optimize management of patients receiving anticoagulants. CONCLUSIONS: Strong recommendations included using patient self-management of international normalized ratio (INR) with home point-of-care INR monitoring for vitamin K antagonist therapy and against using periprocedural low-molecular-weight heparin (LMWH) bridging therapy. Conditional recommendations included basing treatment dosing of LMWH on actual body weight, not using anti-factor Xa monitoring to guide LMWH dosing, using specialized anticoagulation management services, and resuming anticoagulation after episodes of life-threatening bleeding.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Peer-reviewed clinical and outcomes research relevant to medicinal leech therapy and its biology. Indexed in PubMed and verified against the NCBI record.
Por qué esto importa para la hirudoterapia
Esta guía de práctica clínica de la Sociedad Estadounidense de Hematología (ASH) utilizó el marco GRADE y revisiones sistemáticas de la evidencia (respaldadas por el Centro GRADE de la Universidad McMaster) para emitir 25 recomendaciones y 2 declaraciones de buena práctica sobre la optimización de la anticoagulación una vez que se ha elegido un fármaco para la tromboembolia venosa (VTE), incluida una recomendación fuerte para la autogestión del INR por parte del paciente con monitoreo domiciliario a pie de cama para la terapia con antagonistas de la vitamina K y una recomendación fuerte contra la terapia de puente periprocedimental con heparina de bajo peso molecular. Para la hirudoterapia, enmarca el panorama convencional de la anticoagulación farmacológica frente al cual se posicionan los anticoagulantes derivados de sanguijuelas (como hirudin) y la terapia tópica con sanguijuelas en el salvamento de colgajos, y subraya que el manejo de los anticoagulantes sistémicos se rige por evidencia rigurosa y graduada. Advertencia: esta es una guía que sintetiza estudios previos sobre fármacos anticoagulantes sistémicos para VTE; no estudia las sanguijuelas medicinales ni la hirudoterapia y no hace afirmaciones sobre ellas, por lo que constituye un contexto en lugar de evidencia directa para el tratamiento con sanguijuelas.
Citación
American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy.
Witt DM et al. · Blood advances, 2018
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026